688331 RemeGen Co., Ltd.

Watchlist

31.92
-0.93-2.83%

Market Closed Dec 20 15:00 CST

17.38BMarket Cap-11.20P/E (TTM)

About RemeGen Co., Ltd. Company

The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., led by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-in-class and best-in-class biopharmaceuticals, and has created a number of new biopharmaceuticals with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has focused on the field of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. Main products: titasip, verdicitumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.

Company Profile

Short Name-A荣昌生物

Company NameRemeGen Co., Ltd.

Listing DateMar 31, 2022

Issue Price48.00

Shares Offered54.43M share(s)

FoundedJul 4, 2008

Chairmanweidong wang

Legal Representativeweidong wang

General Managerjianmin fang

Secretaryqingkai wen

Employees3615

ProvinceShan Dong Sheng

Phone0535-3573685

Office AddressNo. 58, Beijing Middle Road, Yantai Development Zone, Yantai Area, Shandong Pilot Free Trade Zone, China

Zip Code264006

Registered AddressNo. 58, Beijing Middle Road, Yantai Development Zone, Yantai Area, Shandong Pilot Free Trade Zone, China

Fax0535-6113517

Emailrcsw@remegen.cn

Websitehttp://www.remegen.cn/

Business License91370600676820877R

BusinessThe company was founded in 2008 and is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has focused on the field of therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies.